Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Defining the difference: What Makes Biologics Unique.

Literature DB >> 23393437

Defining the difference: What Makes Biologics Unique.

Abstract

Biologics differ from chemically derived drugs in ways that affect their cost, production, administration, and clinical efficacy. Here's a look at the most important differences and their implications.

Year: 2004 PMID： 23393437 PMCID： PMC3564302

Source DB: PubMed Journal: Biotechnol Healthc ISSN： 1554-169X

Keyword Cloud
Cited

34 in total

1. An improved purification method for the lysosomal storage disease protein β-glucuronidase produced in CHO cells.

Authors: Erica J Fratz-Berilla; Stephanie A Ketcham; Hamideh Parhiz; Muhammad Ashraf; Chikkathur N Madhavarao
Journal: Protein Expr Purif Date: 2017-07-19 Impact factor: 1.650

2. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications.

Authors: Sarah Rogstad; Anneliese Faustino; Ashley Ruth; David Keire; Michael Boyne; Jun Park
Journal: J Am Soc Mass Spectrom Date: 2016-11-21 Impact factor: 3.109

Review 3. Differentiating biosimilarity and comparability in biotherapeutics.

Authors: Valderilio Azevedo; Brian Hassett; João Eurico Fonseca; Tatsuya Atsumi; Javier Coindreau; Ira Jacobs; Ehab Mahgoub; Julie O'Brien; Ena Singh; Steven Vicik; Brian Fitzpatrick
Journal: Clin Rheumatol Date: 2016-10-12 Impact factor: 2.980

Review 4. What are the drugs of the future?

Authors: Huy X Ngo; Sylvie Garneau-Tsodikova
Journal: Medchemcomm Date: 2018-04-23 Impact factor: 3.597

Review 5. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors: Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal: Expert Opin Drug Metab Toxicol Date: 2017-02-22 Impact factor: 4.481

Defining the difference: What Makes Biologics Unique.

1. An improved purification method for the lysosomal storage disease protein β-glucuronidase produced in CHO cells.

2. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications.

Review 3. Differentiating biosimilarity and comparability in biotherapeutics.

Review 4. What are the drugs of the future?

Review 5. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

6. Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.

Review 7. Industrializing engineered autologous T cells as medicines for solid tumours.

8. Biologic adjuvants and bone: current use in orthopedic surgery.

Review 9. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Review 10. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.